<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>University of Chicago Medicine &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/university-of-chicago-medicine/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 16 Oct 2026 05:02:52 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>University of Chicago Medicine &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Low-Dose BCMA CAR-T Therapy Anito-Cel Eradicates Myeloma in All 38 Phase 1 Patients</title>
		<link>https://bioengineer.org/low-dose-bcma-car-t-therapy-anito-cel-eradicates-myeloma-in-all-38-phase-1-patients/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 16 Oct 2026 05:02:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[anito-cel]]></category>
		<category><![CDATA[BCMA]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[D-domain binder]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[Mass General Brigham]]></category>
		<category><![CDATA[multiple myeloma]]></category>
		<category><![CDATA[neurotoxicity]]></category>
		<category><![CDATA[New England Journal of Medicine]]></category>
		<category><![CDATA[Phase 1 clinical trial]]></category>
		<category><![CDATA[relapsed refractory cancer]]></category>
		<category><![CDATA[University of Chicago Medicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=421816</guid>

					<description><![CDATA[A phase 1 trial found that the investigational BCMA-targeted CAR-T therapy anito-cel produced responses in all 38 participants with relapsed or refractory multiple myeloma, with a favorable safety profile and durable long-term benefit.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">421816</post-id>	</item>
	</channel>
</rss>
